Commentary, J Virol Antivir Res Vol: 14 Issue: 2

Understanding Whooping Cough: Insights into Bordetella Pertussis Pathology, Diagnosis, and Therapeutic Approaches

Thomas Demuyser

 Department of Microbiology, University of Antwerp, Edegem, Belgium

*Corresponding Author: Thomas Demuyser 
Department of Microbiology, University of Antwerp, Edegem, Belgium
E-mail: Thomas.d@ue.be

Received date: 12 September, 2024, Manuscript No. JVA-24-147825;
Editor assigned date: 16 September, 2024, PreQC No. JVA-24-147825 (PQ);
Reviewed date: 01 October, 2024, QC No. JVA-24-147825;
Revised date: 12 June, 2025, Manuscript No. JVA-24-147825 (R);
Published date: 19 June, 2025, DOI: 10.4172/2324-8955.1000718.

Citation: Demuyser T (2025) Understanding Whooping Cough: Insights into Bordetella Pertussis Pathology, Diagnosis, and Therapeutic Approaches. J Virol
Antivir Res 14:2.

Description

Bordetella pertussis is the causative agent of whooping cough, a highly contagious respiratory disease characterized by severe coughing fits. Despite the availability of vaccines, whooping cough remains a significant public health concern, particularly in unvaccinated populations and in those with waning vaccine-induced immunity. This manuscript provides a comprehensive review of the pathogenesis, clinical manifestations, diagnostic methods, and management strategies for Bordetella pertussis infection. Whooping cough, also known as pertussis, is an acute respiratory illness caused by the bacterium Bordetella pertussis. This disease is marked by paroxysmal coughing that can lead to significant morbidity and, in severe cases, mortality. Although vaccination has significantly reduced the incidence of pertussis, outbreaks continue to occur, underscoring the need for continued vigilance in diagnosis, treatment, and prevention.

The pathogenesis of Bordetella pertussis involves several key steps

Bordetella pertussis is transmitted through airborne droplets from coughing or sneezing. The bacteria adhere to the ciliated epithelial cells of the nasopharynx using fimbriae and pertussis toxin. Following initial colonization, the bacteria release various virulence factors, including pertussis toxin, adenylate cyclase toxin, and tracheal cytotoxin. These factors contribute to the pathogenicity by disrupting host cell function and immune responses. The pertussis toxin impairs immune responses and interferes with cellular signaling pathways, leading to prolonged infection. The disease progresses through three clinical phases: catarrhal, paroxysmal, and convalescent, with each phase marked by distinct symptoms and severity.

Clinical presentation

Catarrhal stage: Lasts 1-2 weeks. Characterized by mild upper respiratory symptoms such as a runny nose, sneezing, low-grade fever, and mild cough. This stage is highly contagious and can be mistaken for a common cold. Paroxysmal stage: Lasts 1-6 weeks. Marked by severe, spasmodic coughing fits that can end in a high-pitched “whoop” sound during inhalation. The cough is often accompanied by vomiting, exhaustion, and difficulty breathing. This stage is the most characteristic and severe and poses a high risk for complications. Lasts several weeks to months. Coughing fits gradually decrease in frequency and severity. Recovery can be prolonged, and residual cough may persist for several weeks.

Accurate diagnosis of Bordetella pertussis infection involves a combination of clinical evaluation, laboratory tests, and epidemiological considerations. A detailed history of exposure to individuals with whooping cough and the characteristic cough pattern are important in the diagnostic process. Polymerase Chain Reaction (PCR) testing of nasopharyngeal swabs or aspirates is highly sensitive and specific for detecting Bordetella pertussis DNA. It is most effective during the catarrhal and early paroxysmal stages. Isolation of Bordetella pertussis from nasopharyngeal specimens remains the gold standard but is less commonly used due to its lower sensitivity and the technical difficulty of the procedure. Detection of specific antibodies (e.g., anti-pertussis toxin) can aid in diagnosis, particularly in later stages of the disease. However, serological testing is less effective in the early stages and may be affected by previous vaccination. Chest Xray although not diagnostic, it may be used to rule out other causes of cough and to assess for complications such as pneumonia.

Effective management of Bordetella pertussis infection involves both antibiotic therapy and supportive care

Antibiotic therapy: Macrolides (e.g., azithromycin or erythromycin) are the preferred treatment and are most effective when administered during the catarrhal stage or early in the paroxysmal stage. For patients who cannot tolerate macrolides, trimethoprimsulfamethoxazole may be used as an alternative, though it is generally less preferred due to potential side effects and lower efficacy in some populations. Supportive measures include ensuring adequate hydration, using a cool-mist humidifier, and employing techniques to manage cough severity. Close monitoring for complications such as pneumonia or secondary bacterial infections is important, especially in young infants and individuals with underlying health conditions. Prevention of pertussis primarily relies on vaccination and public health measures:

DTP/DTaP vaccine the Diphtheria-Tetanus-Pertussis (DTP) or Diphtheria-Tetanus-Acellular Pertussis (DTaP) vaccines are highly effective in preventing pertussis. The primary series is recommended for infants and young children, with booster doses given during adolescence and adulthood to maintain immunity. Vaccination during pregnancy (preferably between 27-36 weeks' gestation) helps protect newborns through passive immunity. Individuals with pertussis should be isolated to prevent spread and encouraged to practice good respiratory hygiene, including covering coughs and frequent handwashing. Identifying and treating close contacts, particularly unvaccinated or vulnerable individuals, can prevent further spread of the disease.

Conclusion

Bordetella pertussis remains a significant pathogen causing whooping cough, with a clinical presentation characterized by severe coughing fits and potential complications. Early diagnosis using PCR and appropriate antibiotic treatment are crucial for effective management and reducing transmission. Vaccination remains the cornerstone of prevention, with ongoing efforts needed to address vaccine coverage and booster requirements. Continued public health efforts are essential to control outbreaks and protect vulnerable populations from this debilitating disease.